Regulatory T cells (Tregs) and plasmacytoid dendritic cells (pDCs) play important roles in the immune escape of cancer. In this study, we investigated pDCs and pDC-induced inducible costimulator (ICOS) + Treg populations in peripheral blood from gastric cancer (GC) patients and healthy donors by flow cytometry. The distribution of these cells in carcinoma tissue, peritumor tissue, and normal gastric mucosa was detected by immunohistochemistry. Plasma and tissue concentration of the cytokines such as interleukin-10 and transforming growth factor-b1 were also measured. We found that the numbers of pDCs, Tregs, and ICOS + Tregs in peripheral blood were increased in GC patients compared with healthy donors. In tissue, Tregs and ICOS + Tregs were found distributing mainly in carcinoma tissue, whereas pDCs were mainly found in peritumor tissue. Moreover, the Foxp3 + I-COS + ⁄ Foxp3 + cell ratio in carcinoma and peritumor tissue were higher than that in normal tissue. There were more ICOS + Tregs in tumor and peritumor tissue of late-stage GC patients. There was a positive correlation between pDCs and ICOS + Tregs in peripheral blood and peritumor tissue from GC patients. In conclusion, pDCs may play a potential role in recruiting ICOS + Tregs, and both participate in the immunosuppression microenvironment of GC.
A pproximately one million GC cases are estimated to occur every year worldwide, leading to over 700 000 deaths. Gastric cancer accounts for 8% of all cancer cases and 10% of all cancer deaths globally.
(1) Although great progress in treatment methods have been reported, (2, 3) overall survival for patients with GC remains poor. In recent years, there has been great fervor in tumor immunology research. Many immune cells, such as CD4 + CD25
+ regulatory T cells (Tregs) (4, 5) and CD8 + CD28 À T cells, (6) have been found to suppress the function of immune effector cells, thus facilitating the escape of tumor cells from immune surveillance.
Regulatory T cells play an important role in the maintenance of immunological unresponsiveness to self-antigens and are involved in suppressing excessive immune responses deleterious to the host. (7) Previous research has shown that the proportion of Tregs is increased in tumor tissue and peripheral blood from patients with pancreas ⁄ breast adenocarcinoma, prostate cancer, and ovarian and lung cancers. (8) (9) (10) These cells prevent activated CD4 + CD25 À and CD8 + cells from proliferating, thereby mitigating the immune response against tumor antigens, (8) and are related to poor prognosis. (4, 11) Regulatory T cells are further divided into two subsets, ICOS + Tregs and ICOS À Tregs. In vitro, experiments have confirmed that the capacity of cytokine production by the two Treg subsets were different. The ICOS + Tregs could secrete massive amounts of IL-10 and moderate amounts of TGF-b1, whereas the ICOS À Tregs played a suppressive function mainly through the secretion of TGF-b1. (12) In mice, ICOS + Tregs are characterized by superior survival and highly suppressive properties compared with ICOS À Tregs. (13) In human melanoma, ICOS + Tregs were the main suppression subset. (14) Therefore, the two subsets of Tregs exert different functions in the same environment. Although increased Treg numbers have been found in peripheral blood, tumor tissue, and perigastric lymph nodes in GC patients and model animals, (4, 5, 15) the role of Treg subsets in tumor immune escape of GC remains unclear.
Plasmacytoid dendritic cells are involved in protective immunity and tumor immune escape. Under steady state condi-tions, they are present in blood and absent from peripheral tissues. They can secrete large amounts of type I IFNs and thereby participate in antiviral innate immunity. (16) Recent evidence suggests that in some solid cancers they may regulate antitumor immunity and support tumor immune evasion. Zou et al. (17) found a large number of pDCs in the malignant ascetic fluid of advanced-stage ovarian cancer patients; in breast cancer, pDC numbers negatively correlate with overall survival and relapse-free survival. (18) One of the possible molecular mechanisms by which pDCs mediate immune suppression is to induce ICOS + Tregs by upregulating the expression of ICOS-L. (12, 19) However, whether the pDC prevalence is increased in GC is still unclear. Importantly, there is a paucity of studies presenting the association between ICOS + Tregs and pDCs in GC. To address these issues, the frequency of circulating pDCs, Tregs, and ICOS + Tregs were analyzed in GC patients in various advanced stages. These cells were also compared in carcinoma tissue, peritumor tissue, and normal gastric mucosa tissue. Our results showed that GC patients had increased numbers of ICOS + Tregs, particularly in situ tumor and peritumor tissue, which correlated with tumor stage. Moreover, the pDCs were also increased in GC and there was a positive correlation between pDCs and ICOS + Tregs in peripheral blood and peritumor tissue.
Materials and Methods
Ethics. Prior to the research, appropriate permission was granted by the ethical committee of the First Affiliated Hospital, Medical College, Zhejiang University (Hangzhou, China). All participants provided their written informed consent to participate in this study.
Study subjects. Blood samples. After elimination of those with other malignancies, autoimmune diseases, or chronic infections, 51 patients were enrolled in the study, all of whom were diagnosed with GC by gastroscopic biopsy. Peripheral blood (~5 mL) was collected from each patient in EDTA tubes prior to antitumor treatment. Thirty healthy individuals (23 male, 7 female; average age, 56 AE 13 years) who were selected based on health inspection were enrolled as controls. Peripheral blood was also obtained. There was no significant difference in gender or age between the patient and control groups. After centrifugation at 300g for 5 min, plasma was frozen at À80°C for later ELISA. Peripheral blood mononuclear cells were analyzed by flow cytometry.
Tissue samples. Ninety-one patients with gastric cancer were enrolled, all of whom underwent surgery between 2009 and 2011. No patient received radiotherapy or chemotherapy before surgery. Patients with a history of autoimmune disease or chronic infection were excluded. Tissue from 30 patients was randomly selected from a total of 91 patients for immunofluorescence analysis (17 male, 13 female; average age, 62 AE 10 years; TNM stage I, 9; stage II, 5; stage III, 5; IV, 11). Tissue from 15 patients was randomly selected from a total of 91 patients for Western blot analysis (8 male, 7 female; average age, 63 AE 11 years; TNM stage: I, 5; II, 3; III, 5; IV, 2).
The clinical characteristics of the patients who provided blood and tissue samples are shown in Table 1 .
Flow cytometry analysis. Multicolor flow cytometry was carried out on fresh Ficoll-prepared (TBD Sciences, Tianjing, China) PBMCs. After suspension in PBS, PBMCs (100 lL) were separately added to two tubes (1 9 10 6 -2 9 10 6 PBMCs per sample). The first tube was incubated with FITC-Lineage (CD2, CD3, CD14, CD16, CD19, CD235a, and CD56), APC-HLA-DR, PE-Cy7-CD11c, and Percp-Cy5. 
Foxp3
+ Tregs and analyze their ICOS expression. Briefly, after CD4-FITC (BD Pharmingen, San Diego, CA, USA), CD25-PE-Cy5 (BD Pharmingen) and ICOS-PE-Cy7 (eBioscience) surface staining, PBMCs were washed and fixed with fixation ⁄ permeabilization solution (eBioscience), then incubated with anti-Foxp3-PE mAbs (eBioscience). After washing, stained cells were analyzed on a flow cytometer (LSR-II; BD Biosciences) using BD FACSDiva Software. Lymphocytes (1-3 9 10
4 ) were gated to analyze the Tregs. Considering the small proportion of pDCs, 100 000-200 000 events in the lymphocytes and monocytes were accumulated as the acquisition gates. The appropriate isotype was used.
Immunohistochemistry. Standard H&E staining was used to confirm the pathological diagnosis, and the peritumor region was defined as a 2-5-cm zone bordering the margin of the gastric tumor. Paraffin-embedded, 4-lm-thick sections of normal mucosa, peritumor mucosa, and cancer tissue from each patient were selected for IHC analysis. Sections were dewaxed and then subjected to heat-induced epitope retrieval with preheated epitope retrieval solution (10 mM citrate buffer, pH 6.0). Next, endogenous peroxidase activity was blocked and the sections were incubated overnight with one of the following primary mAbs: mouse anti-CD3, rabbit anti-CD8 (working solution; both Zhongshan Golden Bridge Biotechnology, Beijing, China), rabbit anti-CD4 (1:100; Leica, Wetzlar, Germany), or mouse anti-FoxP3 (1:400; Abcam, Cambridge, UK). After incubation with HRP-conjugated second antibody (Invitrogen, Carlsbad, CA, USA) and development with diaminobenzidine, sections were counterstained with hematoxylin.
Because available anti-BDCA-2 antibodies (1:500; MACS, Bergisch Gladbach, Germany; source: mouse) are not suitable for paraffin-embedded archive material, BDCA-2 analysis was carried out on frozen sections. After confirmation of the diagnosis by H&E staining, 5-lm sections were immersed in precooled acetone (À20°C) for 30 min. Endogenous peroxidase was quenched in 3% H 2 O 2 . The sections were then incubated overnight at 4°C with primary mAb. Subsequent steps were as described above. Negative control staining was carried out with cold PBS in place of primary antibody.
Immunofluorescence. For Foxp3 and ICOS, double-fluorescence immunostaining was carried out in 30 randomly selected GC patients. The first day of the experiment was the same as for IHC analysis of paraffin-embedded sections, except that endogenous peroxidase activity was not blocked and the primary mAb was a FoxP3 and ICOS cocktail (both 1:200; Abcam). On the next day, sections were incubated with a cocktail of donkey antimouse (Alexa Fluor 488, 1:300) and donkey anti-rabbit (Alexa Fluor 594, 1:200) antibodies (both from Invitrogen). Finally, 30 lL mounting solution antifade + DAPI (Vector Laboratories, Burlingame, CA, USA) was applied and the sections were covered with coverslips. The sections were photographed under a fluorescence microscope (940 objective lens, 910 ocular lens; Olympus, Tokyo, Japan) with NIS-Elements software (Nikon Corporation, Tokyo, Japan).
Western blot analysis. Fifteen cases were selected for Western blotting. Tissue samples were lysed in pre-cooling RIPA lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 1 mM PMSF). Protein concentration was quantified using the Bradford method. Then SDS-PAGE was used to separate the extracted proteins, which were then transferred to PVDF membranes. After blocking with TBS-T buffer containing 5% non-fat powdered milk for 2 h, the membranes were immunoblotted overnight with primary antibody, mouse anti-IL-10 (1:1000) and mouse anti-TGF-b1 (1:1000) (both Abcam). Horseradish peroxidase-conjugated goat anti-mouse IgG was used as the secondary antibody. b-Actin (1:1000; SigmaAldrich, St. Louis, MO, USA) was used as an internal control. Immunoreactive bands on the blots were visualized with an enhanced chemiluminescence reagent ECL kit (Beit Haemek, Kibbutz Beit Haemek, Israel).
Immunosorbent assay. Plasma from GC patients and control donors previously stored at À80°C was thawed and analyzed for concentrations of IL-10, IFN-a, IL-2, and TGF-b1 using a human platinum ELISA kit (eBioscience). The assay was run according to the manufacturer's test protocol. All of the samples (except for those for TGF-b1) were added without dilution because of the low levels of the cytokines based on the results of pilot experiments. Each blank, standard, and optional control sample was assayed in duplicate. Absorbances were measured on a microplate reader (ELx800; BioTek, Winooski, VT, USA) with a primary wavelength of 450 nm and a reference wavelength of 630 nm.
Statistical analysis. Data were summarized by descriptive statistics in SPSS 16 .0 (SPSS Inc., Chicago, IL, USA). Flow cytometry and ELISA data were analyzed by unpaired Student's t-test for normal distribution data which were expressed as the mean AE SD, or Mann-Whitney test for abnormal distribution data which were expressed as median (range There was an increased number of circulating Tregs in GC patients compared to the control group (4.69 AE 1.72% vs 3.38 AE 1.04%, P = 0.001; Fig. 1a,b) . Moreover, the number of (Fig. 2a,c) . These results collectively suggest high enrichment of Tregs in GC patients.
We further analyzed Treg subsets according to ICOS expression (Fig. 1c) . In peripheral blood, the proportion of Treg subsets in CD4 + T cells in control individuals was 1.10% (range, 0.30-1.90%) for ICOS + Tregs and 2.15% (range, 0.50-4.30%) for ICOS À Tregs; the values in GC patients were 1.50% (range, 0.50-4.10%) and 2.80% (range, 0.60-7.40%), respectively.
Numbers of both ICOS
+ Tregs and ICOS À Tregs were significantly increased in GC patients (P = 0.003 and P = 0.007, respectively) (Fig. 1d) . In tissue, we carried out double immunofluorescence staining of Foxp3 and ICOS (Fig. 2b) (Fig. 3a) . The proportion of circulating pDCs among Lineage À cells was significantly higher in GC patients than in control donors (2.64% [range, 0.14-10.70%] vs 1.51% [range, 0.11-6.91%], P = 0.027; Fig. 3b) .
Immunohistochemical staining of BDCA-2 revealed that pDCs were present in stomach tissues of GC patients. Strikingly, the number of pDCs in peritumor tissue (0.60 [range, 0.00-4.90]) was higher than that in cancer tissue (0.30 [range, (Fig. 4a,b) .
Positive correlation between pDCs and ICOS + Tregs in blood and peritumor tissue. As described above, circulating pDCs, total Tregs, and two subsets of Tregs were significantly increased in GC patients. Furthermore, we found that the prevalence of pDCs was significantly associated with that of ICOS + Tregs in peripheral blood (r = 0.431, P = 0.002; Fig. 3c ). In Fig. 4c ), but not in tumor tissue. There was no significant correlation between pDCs and ICOS À Tregs (Fig. S2 ).
Highly enriched ICOS + Tregs in tumor and peritumor tissue of advanced stage GC patients. To further investigate the changes in Tregs and pDCs during tumor invasion, we compared the pDCs, total Tregs, and Treg subsets in the blood and tissue of GC patients at different TNM stages and LN metastasis statuses. As shown in Figure 5 , we observed increasing ICOS + Tregs in the tumor and peritumor tissue of subjects as follows: stage I and II < stage III and IV (P = 0.011 in tumor tissue and P = 0.046 in peritumor tissue); LN-negative group < LN metastasis group, although the trend did not reach statistical significance. (Fig. S3) .
Elevated IL-10 levels in tissue and plasma, and decreased plasma IFN-a level in GC patients. To study the changes in the concentrations of cytokines in gastric tissue, we first analyzed frozen tissue by Western blotting. As shown in Figure 6(a) , the concentration of IL-10 was highest in the carcinoma tissue, followed by peritumor tissue, and lowest in normal tissue. Normal tissue had a lower concentration of TGF-b1 than tumor tissue and peritumor tissue, their levels in tumor tissue and peritumor tissue were similar.
Plasma levels of IL-10 and IL-2 were higher in patients with GC than in control subjects (IL-10, 4.452 [range, 3.600-8.275] pg ⁄ mL vs 3.847 [range, 3.375-7.663] pg ⁄ mL; IL-2, 7.351 [range, 6.260-9.980] pg ⁄ mL vs 6.396 [range, 5.854-9.700] pg ⁄ mL, both P < 0.001; Fig. 6b ). The plasma IFN-a level was below the detection limit of the ELISA kit (3.2 pg ⁄ mL) in most GC patients and above the detection limit in most age-and gender-matched healthy individuals. There was a statistically significant decrease in IFN-a levels in GC patients. We did not find any difference in plasma TGF-b1 levels between the two groups (13 651 AE 4424 pg ⁄ mL in GC patients vs 12 926 AE 3609 pg ⁄ mL in control donors, P = 0.463) (Fig. S4) .
Discussion
Ineffective antitumor immune responses contribute to tumor growth and metastasis. Regulatory T cells are considered to be indispensable players in immunological tolerance. Nevertheless, the subset of Tregs that plays the key role in tumor immune escape remains largely undefined. In the present study, we found humans with GC had increased Tregs in peripheral blood and carcinoma tissue, which was consistent with previous reports. (5, 8, 10) (20) In this study, we showed that ICOS + Tregs in both carcinoma tissue and peritumor tissue increased with the progress of tumor stage in GC patients. This correlation with tumor stage was not revealed on total Tregs or ICOS À Tregs (data not shown), suggesting that the number of ICOS + Tregs is more closely linked with the severity of disease.
a-Interferon has been shown to affect tumor cell proliferation and tumor metastasis. (21) As an important source of IFN-a, pDCs may be important players in the tumor immune microenvironment. In lung cancer, activated pDCs could induce a cytotoxic T cell response relevant to antitumor immunity. (22) Notably used for treatment, stimulated pDCs have been reported to induce tumor regression. (23) However, the antitumor effect of pDCs has been questioned recently. It has been shown that pDCs are recruited to solid tumor tissues and are associated with poor clinical outcome. (18, 24) Plasmacytoid dendritic cells that infiltrate the tumor microenvironment present a fragmentary function. Only limited expression of the IFN-a-inducible intracellular protein MxA in pDCs in cancer tissue (18, 25) and those deficient in IFN-a production promote the expansion of Foxp3 + Tregs. (26) In tumor ascites of ovarian cancer, pDCs took part in immunosuppression by inducing IL-10-producing ICOS + Tregs. (20) In a mouse model of lung cancer, pDC induced an immunosuppressive environment through an influx of Tregs, which was associated with tumor growth. (27) In vitro experiments have confirmed that both maturing and mature pDCs upregulate the expression of ICOS-L and have the ability to drive the generation of Tregs from na€ ıve CD4 + T cells through an ICOS-L-ICOS pathway. (12, 19) This potential of pDCs to express ICOS-L and induce the generation of Tregs had nothing to do with whether they are mature or not. (28) In the current study, we have shown that pDC numbers in peripheral blood were significantly increased in GC patients. Interestingly, pDCs preferentially accumulated in peritumor tissue rather than tumor tissue. This distribution bias has also been reported in cervical neoplastic lesions, in that pDCs were mainly detected in the stroma underlying the tumor rather than within the cancerous epithelium. (29) We also found a positive correlation between pDCs and ICOS + Tregs both in peritumor tissue and peripheral blood of GC patients, suggesting that in GC, pDCs may contribute to the differentiation of na€ ıve CD4 + T cells into ICOS + Tregs. Moreover, the plasma concentration of IFN-a was lower in GC patients, although the number of pDCs increased in peripheral blood. This skewing of the function of pDCs may contribute to the immune escape of GC.
Interleukin-2 plays an important role in the immune escape of cancer. It can maintain the expression of Foxp3 in Tregs. (30) Zou et al. reported that large quantities of IL-2 could activate Treg division without MHC class II and T cell antigen receptor signaling. (31) Furthermore, in the presence of IL-2, ICOS-L could efficiently induce the proliferation of ICOS + Tregs. (12) In our study, there was a statistically significant increase in plasma IL-2 level in patients with GC, suggesting its involvement in the GC immune escape network.
Using IHC staining, we found the distribution of T cell subsets was different in carcinoma tissue, peritumor tissue, and normal tissue. There were more CD4 + T cells but fewer CD8 + T cells in carcinoma tissue compared with normal tissue and peritumor tissue. We thought the increased CD4 + T cells were Tregs and the loss of CD8 + cytotoxic T cells was probably due to apoptosis induced by Tregs. (32, 33) In conclusion, in our study, we found that a variety of immune regulatory cells and cytokines were involved in the immunosuppressive environment of GC. Increased numbers of pDCs might contribute to the immunosuppression of GC by inducing ICOS + Tregs. The gathering of ICOS + Tregs might lead to progression of disease. Our findings provide new insights into the tumor immunology of pDCs and ICOS + Tregs in GC patients. Therapy targeting ICOS-L ⁄ ICOS costimulation could reduce expansion of ICOS + Tregs and become a potential treatment for gastric cancer.
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